73 results
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Current report (foreign)
5:29pm
and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened … or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing
424B5
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Prospectus supplement for primary offering
5:26pm
by anyone for any purpose other than in connection with the distribution of Common Shares under this offering. The Company does not undertake to update … , as of the date hereof, to be incorporated by reference in the accompanying Prospectus only for the purpose of the distribution of the Common Shares
424B5
IPA
ImmunoPrecise Antibodies Ltd
7 Dec 23
Prospectus supplement for primary offering
4:53pm
of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should … that no stop order suspending the effectiveness of the Registration Statement be in effect and that no proceedings for this purpose have been initiated
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
6 Dec 23
Current report (foreign)
5:19pm
as of the date hereof to conduct its business purpose in a manner substantially similar to that described in the Registration Statement, the Pricing … of the Securities Act) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could
6-K
EX-8.1
IPA
ImmunoPrecise Antibodies Ltd
6 Dec 23
Current report (foreign)
5:19pm
this opinion in connection with the filing of the Prospectus Supplement and this opinion is not to be relied upon for any other purpose without our prior
424B5
k5d0wk
5 Dec 23
Prospectus supplement for primary offering
4:02pm
6-K
EX-99.1
iry5zog3lvzs0k
20 Oct 23
Current report (foreign)
2:56pm
6-K
EX-99.1
6k5mf2b lhx
18 Sep 23
Statement of Executive Compensation
2:47pm
6-K
EX-5.1
85uit y9pa0
15 Aug 23
Current report (foreign)
5:50pm
6-K
EX-10.1
novs9ko3w3we8
15 Aug 23
Current report (foreign)
5:50pm
424B5
q8r44
15 Aug 23
Prospectus supplement for primary offering
5:47pm
F-3
EX-4.3
ixam6kzie20k9idy
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
mqfwaw5ulj41rmv ep
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
t2j18soi47xuwsm ql
10 Jul 23
Shelf registration (foreign)
7:04pm
40-F
jsatz95hvbti2dw
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.2
216uepl7m
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.1
ikpecdm7lqc
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.3
79tjlw3j
10 Jul 23
Annual report (Canada)
4:32pm
6-K
EX-99.1
lx1vjebfdbz nnbmgj
24 Apr 23
Current report (foreign)
10:01am
6-K
EX-99.1
alg9jzmnzg 7dh
15 Dec 22
Current report (foreign)
8:00am